Jump to Main Content
The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing
- Fisher, Adam C., Kamga, Mark-Henry, Agarabi, Cyrus, Brorson, Kurt, Lee, Sau L., Yoon, Seongkyu
- Trends in biotechnology 2019 v.37 no.3 pp. 253-267
- biopharmaceuticals, biotechnology, cell culture, manufacturing, product quality, production costs
- There is a trend across the pharmaceutical sector toward process intensification and continuous manufacturing to produce small-molecule drugs or biotechnology products. For biotechnology products, advancing the manufacturing technology behind upstream and downstream processes has the potential to reduce product shortages and variability, allow for production flexibility, simplify scale-up procedures, improve product quality, reduce facility footprints, increase productivity, and reduce production costs. On the upstream side of biotechnology manufacturing, continuous perfusion cell cultures are fairly well established. However, truly integrated continuous biomanufacturing requires the uninterrupted connection of continuous unit operations (upstream and downstream) with no isolated intermediate or hold steps occurring between them. This work examines the current scientific and regulatory landscape surrounding the implementation of integrated continuous biomanufacturing.